How Does Retatrutide Work?

Retatrutide works by mimicking the action of three naturally occurring hormone pathways involved in appetite, digestion, blood sugar control and energy balance.

These are:

• GLP-1
• GIP
• glucagon

Because retatrutide activates all three receptors, it is known as a triple agonist. This means it works differently from GLP-1-only medicines and dual agonist medicines.

In simple terms, retatrutide may help reduce hunger, increase fullness after eating, support insulin release when blood sugar is high and influence how the body uses stored energy.

Retatrutide does four main things in the body:

These effects may explain why retatrutide has produced substantial weight loss in clinical trials. However, it is still being studied and is not currently approved for routine medical use.

Why is retatrutide called a triple agonist?

Retatrutide is called a triple agonist because it activates three hormone receptors: GLP-1, GIP and glucagon.

An agonist is a substance that activates a receptor in the body. Retatrutide is designed to activate these three receptors in a way that affects appetite, fullness, glucose control and metabolism.

This triple action is the main difference between retatrutide and many existing weight loss medicines.

The 3 hormones retatrutide mimics

GLP-1: appetite and fullness

GLP-1 is one of the main hormone pathways involved in appetite control.

By activating GLP-1 receptors, retatrutide may help reduce hunger and increase feelings of fullness after eating. It may also slow how quickly food leaves the stomach, which can help people feel satisfied for longer.

GLP-1 activity also helps the pancreas release insulin when blood sugar is high. This is one reason medicines acting on GLP-1 pathways can affect both weight and blood sugar.

GIP: insulin response and metabolism

GIP stands for glucose-dependent insulinotropic polypeptide.

GIP is released after eating and helps the body respond to nutrients. It can support insulin release when blood sugar levels are raised.

In retatrutide, GIP activity may work alongside GLP-1 activity to improve metabolic control. This may help explain why retatrutide is being studied for both obesity and type 2 diabetes.

Glucagon: energy use and fat metabolism

Glucagon is a hormone involved in energy balance.

Unlike GLP-1 and GIP, glucagon has a stronger role in how the body uses stored energy. By activating glucagon receptors, retatrutide may increase energy expenditure and influence fat metabolism.

This does not mean retatrutide is simply a “fat burner”. Its effects are more complex. The glucagon pathway is one part of a wider mechanism involving appetite, fullness, insulin response and energy balance.

Retatrutide is different from many existing weight loss treatments because it is being studied as a triple agonist.

This means it acts on three hormone receptor pathways involved in appetite, fullness, blood sugar control and energy balance. Some licensed weight loss injections act on one or two of these pathways, whereas retatrutide is being studied for its effect on three.

This broader mechanism may help explain why retatrutide has shown strong results in clinical trials. However, retatrutide is still investigational and is not currently approved in the UK.

This does not mean retatrutide is better or more suitable than existing licensed treatments. The right treatment depends on a patient’s BMI, medical history, current medicines, side effect risk and clinical assessment.

Further reading: Retatrutide results

Retatrutide may help improve blood sugar regulation.

It can activate hormone pathways that support insulin release when blood sugar is high. Clinical trials have shown improvements in A1C, which is a blood test used to measure average blood sugar levels over time.

Retatrutide is being studied in people with obesity, overweight and type 2 diabetes, but it is not currently approved as a diabetes or weight loss treatment in the UK.

Retatrutide may influence energy use through its glucagon receptor activity.

This is one of the reasons it is different from GLP-1-only treatments. Glucagon is involved in energy regulation and may affect how the body uses stored fuel.

However, retatrutide should not be described as a simple metabolism booster. Its weight loss effects are likely due to several combined actions, including appetite reduction, increased fullness, glucose regulation and changes in energy balance.

Retatrutide may support fat loss as body weight decreases, but it is not simply a fat-burning injection.

Its glucagon activity may influence how stored energy is used, while its GLP-1 and GIP activity may help reduce food intake and support blood sugar control. Together, these effects may lead to weight loss and reductions in body fat.

Retatrutide does not specifically target one area of fat, such as belly fat. Fat loss usually occurs across the body over time and typically increases as the dose is increased.

Further reading: Retatrutide dosage guide

Retatrutide works by activating three hormone receptors: GLP-1, GIP and glucagon.

This triple action may reduce appetite, increase fullness, support blood sugar control and influence how the body uses energy. These combined effects may explain why retatrutide has produced significant weight loss in clinical trials.

However, retatrutide remains an investigational medicine. It is not currently approved in the UK and cannot legally be prescribed or bought as a licensed weight loss treatment.

Further reading: How to get retatrutide